Ayr Wellness Past Earnings Performance
Past criteria checks 0/6
Ayr Wellness's earnings have been declining at an average annual rate of -26.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 30.2% per year.
Key information
-26.3%
Earnings growth rate
34.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 30.2% |
| Return on equity | -43.4% |
| Net Margin | -48.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ayr Wellness makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 465 | -223 | 166 | 0 |
| 30 Jun 24 | 465 | -191 | 160 | 0 |
| 31 Mar 24 | 464 | -183 | 165 | 0 |
| 31 Dec 23 | 464 | -86 | 178 | 0 |
| 30 Sep 23 | 463 | -190 | 203 | 0 |
| 30 Jun 23 | 457 | -206 | 215 | 0 |
| 31 Mar 23 | 440 | -211 | 216 | 0 |
| 31 Dec 22 | 421 | -207 | 213 | 0 |
| 30 Sep 22 | 419 | -51 | 195 | 0 |
| 30 Jun 22 | 406 | -21 | 182 | 0 |
| 31 Mar 22 | 399 | -6 | 169 | 0 |
| 31 Dec 21 | 358 | -17 | 144 | 0 |
| 30 Sep 21 | 294 | -42 | 113 | 0 |
| 30 Jun 21 | 243 | -38 | 90 | 0 |
| 31 Mar 21 | 180 | -27 | 75 | 0 |
| 31 Dec 20 | 155 | -25 | 72 | 0 |
| 30 Sep 20 | 140 | -41 | 77 | 0 |
| 30 Jun 20 | 126 | -16 | 82 | 0 |
| 31 Mar 20 | 109 | -42 | 71 | 0 |
| 31 Dec 19 | 75 | -164 | 49 | 0 |
| 30 Sep 19 | 43 | -191 | 31 | 0 |
| 30 Jun 19 | 11 | -242 | 11 | 0 |
| 31 Mar 19 | 0 | -209 | 3 | 0 |
Quality Earnings: AYRW.F is currently unprofitable.
Growing Profit Margin: AYRW.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AYRW.F is unprofitable, and losses have increased over the past 5 years at a rate of 26.3% per year.
Accelerating Growth: Unable to compare AYRW.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AYRW.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: AYRW.F has a negative Return on Equity (-43.37%), as it is currently unprofitable.